Transplantatation of scaffold-free spheroids composed of synovium-derived cells and chondrocytes for the treatment of cartilage defects of the knee.
Transplantatation of scaffold-free spheroids composed of synovium-derived cells and chondrocytes for the treatment of cartilage defects of the knee.
复制标题
DOI：
10.22203/ecm.v022a21
复制
发表时间：
2011-11
影响因子：
3.1
通讯作者：
J. I. Lee;M. Sato;H. W. Kim;J. Mochida
中科院分区：
文献类型：
--
作者：
J. I. Lee;M. Sato;H. W. Kim;J. Mochida
自体软骨细胞植入（ACI）是骨关节炎的首选治疗方法。然而，为了使用这种方法再生关节软骨，该过程自相矛盾地要求用于离体扩增的关节软骨细胞（AC）的细胞来源来自患者自己的健康软骨，这可能导致供体部位发病。因此，有必要开发AC的替代品。在本研究中，我们研究了滑膜来源细胞 (SY) 是否可以用作 ACI 中 AC 的部分替代品。分离培养家兔膝关节ACs和SYs，并比较细胞的生长速度。为了制造细胞移植物，我们开发了一种高密度悬浮振荡培养方法（HDSS），该方法使细胞在培养基中循环，促进无支架细胞聚集体的自组装。使用 HDSS 将 AC 和 SY 以不同比例混合。收获可注射细胞移植物并将其移植到全层骨软骨缺损中。同时，用甲苯胺蓝和番红O进行组织学评估，并对I型和II型胶原进行免疫组织化学分析。还进行了基因表达来评估软骨细胞特异性分化。我们使用混合 AC 和 SY 在短时间内成功制备了大量的球体（球状细胞聚集体），适用于所有细胞组成比例。我们的数据表明，移植的最小治疗单位有助于软骨的原位再生。总之，在大面积骨关节炎病变患者的 ACI 临床病例中，SY 可以用作 AC 的替代品。
Autologous chondrocyte implantation (ACI) is the treatment of choice for osteoarthritis. However, to regenerate articular cartilage using this method, the procedure paradoxically demands that the cell source of the articular chondrocytes (ACs) for ex vivo expansion be from the patient's own healthy cartilage, which can result in donor site morbidity. Accordingly, it is essential to develop a substitute for AC. In the present study, we investigated whether synovium-derived cells (SYs) could be used as a partial replacement for ACs in ACI. ACs and SYs from the knees of rabbits were isolated and cultured, and the growth rates of the cells were compared. To manufacture the cellular transplants, we developed a high-density suspension-shaking culture method (HDSS), which circulates the cells in culture media, promoting self-assembly of scaffold-free cellular aggregates. ACs and SYs were mixed in various ratios using HDSS. Injectable cellular transplants were harvested and transplanted into full-thickness osteochondral defects. Simultaneously, histological evaluations were conducted with toluidine blue and safranin O, and immunohistochemistry of collagen type I and II was conducted. Gene expression to evaluate chondrocyte-specific differentiation was also performed. We successfully prepared a large quantity of spheroids (spheroidal cell aggregates) in a short time using mixed ACs and SYs, for all cellular composition ratios. Our data showed that the minimal therapeutic unit for the transplants contributed to in situ regeneration of cartilage. In summary, SYs can be used as a replacement for ACs in clinical cases of ACI in patients with broad areas of osteoarthritic lesions.